The proportion of people living with HIV/AIDS in the ageing population (> 50 years old) is increasing. We aimed to explore the relationship between older age and treatment outcomes in HIV-positive persons from the Asia Pacific region.
Introduction
After the scale-up of combination antiretroviral therapy (cART) in both resource-rich and resource-limited countries, most treated HIV-positive patients experience longer survival [1] . As the roll-out of frequent HIV testing is expanded, an increasing proportion of new HIV diagnoses are found in older people [2, 3] . Reasons for increases in new infections in older populations are multifactorial. Although HIV is transmitted at all ages, older individuals may be less inclined to be offered or request HIV testing as a consequence of both provider and patient perception of lack of risk [2] . In addition to HIV-positive patients surviving longer and a higher rate of diagnoses made in older individuals, there are now many older persons living with HIV/AIDS [4, 5] .
It has been suggested that HIV infection is associated with both physical and immunological changes commonly found in HIV-negative ageing populations. Desquilbet et al. [6] reported that HIV-1 infection was associated with earlier occurrence of frailty (physical shrinking; unintentional weight loss; self-reported exhaustion; low physical activity; slowness; weakness of grip strength) and risk of exhibiting 'frailty' increased with duration of HIV infection. Exposure to HIV (including viral suppression) and long-term cART has been suggested to accelerate the body's natural ageing processes as a result of persistent immune activation and treatment-induced pro-inflammatory effects leading to premature immunosenescence (ageing of the immune system) [7] [8] [9] [10] [11] [12] . Furthermore, despite the clear success of cART, HIV-positive people appear to have an increased risk of serious ageing-related diseases including cardiovascular, liver and kidney diseases, malignancies and bone disorders [13, 14] .
The additive effects of immunological changes associated with natural ageing and those resulting from HIV infection may affect the response to cART in ageing populations. Previous studies have shown that older populations have slower increases in CD4 count after starting cART [15] [16] [17] [18] , even though older HIV-positive patients are more likely to achieve and maintain HIV RNA viral load suppression compared with younger patients [16] [17] [18] [19] [20] [21] . The population-level response to cART and subsequent adherence and access to continual cART influence patterns of all-cause mortality. While it is expected that older HIVpositive persons would have a higher risk of mortality compared with the younger population, comparing against general population mortality rates, a notable excess risk differential exists across all age groups [22, 23] . There are minimal data published directly comparing ageing associations for typical HIV treatment outcomes in resource-rich and resource-limited settings.
The objective of this analysis was to explore the relationship between older age and typical HIV treatmentrelated outcomes. We aimed to examine the associations between older age and all-cause mortality; older age and mean CD4 cell count change in response to antiretroviral therapy (ART); older age and the odds of detectable HIV RNA viral load; older age and time to first major treatment modification. The primary aim of this study was to establish and compare the patterns of older age associations in a cohort of patients from both resource-rich and resourcelimited countries.
Methodology

Study population
The Asia Pacific HIV Observational Database (APHOD) is part of the International Epidemiological Databases Evaluating AIDS (IeDEA) collaboration and consists of two adult cohorts, the Australian HIV Observational Database (AHOD) and the TREAT Asia HIV Observational Database (TAHOD), as well as one paediatric cohort, the TREAT Asia Paediatric HIV Observational Database (TApHOD). This study includes the AHOD and TAHOD adult cohorts only. AHOD data are collected from 27 clinical sites throughout Australia, including hospitals, sexual health clinics and clinics of general practitioners. Prospective data collection commenced in 1999 and retrospective data are provided where available. Patients' written and informed consent to participate is obtained at the time of enrolment. TAHOD data are primarily collected from 17 tertiary clinical sites throughout Asia. Prospective data collection commenced in 2003 and retrospective data are provided where available. Patients' written and informed consent is obtained at enrolment at sites where it is required by the local ethics committee; otherwise, data at sites are collected anonymously. Ethics approval for APHOD was granted to all participating sites by relevant institutional review boards. All APHOD study procedures were developed in accordance with the revised 1975 Helsinki Declaration.
Twice annually (in March and September), data for AHOD and TAHOD are collected on a core set of demographic and clinical variables and transferred electronically to the Kirby Institute, University of New South Wales Australia, Sydney, Australia. A detailed description of each cohort has been provided previously elsewhere, and data are subjected to quality control and quality assurance standardized procedures [24, 25] . All patients with at least one follow-up visit and who were recruited up to March 2010 for AHOD and September 2009 for TAHOD were included in the analysis. We further restricted our analysis population to patients initiating cART without any prior exposure to ART (treatment-naïve only).
Statistical analysis
We defined an older patient as having calendar year age > 50 years. We tabulated demographics and clinical characteristics of the study population stratified by age group (younger/older).
Cox proportional hazards (PH) models adjusted for fixed and time-updated covariates were used to estimate the hazard ratio (HR) of older age and the association with all-cause mortality (composite endpoint of AIDS-related and non-AIDS-related deaths) and, separately, the association of older age with time to first major treatment modification. We defined a treatment modification as a change from the original regimen of at least two drugs or the addition (or subtraction) of a new class of antiretroviral. Treatment modifications for any reason were include as endpoints, including modification because of toxicity/side effects, virological failure, patient or physician decision, and unknown. Follow-up time was measured from the date of cART initiation or cohort enrolment for the mortality endpoint, whichever came later, and time to first treatment modification was measured from the initiation of cART. Patients were censored if not seen at the clinic for 12 months prior to the site administration censoring date of 30 September 2009 for TAHOD, or 31 March 2010 for AHOD.
Absolute differences in CD4 cell count (cells/μL) compared with pre-cART CD4 counts were examined at 6, 12, 18 and 24 months' duration of cART. We used generalized estimating equations (GEEs), assuming an exchangeable correlation structure to account for within-patient variation of the data. A logistic GEE with an exchangeable correlation structure was used to estimate the odds ratios (ORs) associated with older age and the probability of having a detectable viral load (defined as plasma HIV RNA > 400 HIV-1 RNA copies/mL) at 6, 12, 18 and 24 months' duration of ART. We conducted sensitivity analyses to examine the robustness of our results. Based on previous analyses, we examined different model specifications for our CD4 count modelling [26] [27] [28] and evaluated the influence of reduced viral load testing at some participating TAHOD clinics by restricting the data to complete-case analyses [29] .
Multivariable models (both Cox proportional hazards and GEE) were adjusted for sex; likely mode of HIV exposure [homosexual, heterosexual, injecting drug user (IDU), other or missing]; AIDS illness (yes or no); cohort (AHOD or TAHOD); calendar year (< 1999, 1999-2001, 2002-2004, 2005-2007 or 2008-2010) ; and, if appropriate, timeupdated CD4 count (< 50, 50-99, 100-199, 200-349, 350-500 or > 500 cells/μL or missing); viral load (HIV RNA ≤ 400 or > 400 copies/mL or missing) and duration of cART (6, 12, 18 or 24 months). Multivariable model covariates were added to the model a priori and no form of model selection was considered. For each endpoint, an interaction term between age and cohort was fitted to statistically assess any significant differences in cohort ageing effects. We assumed 'intention to continue treatment' and ignored any changes, interruptions or the termination of treatment after initiation of cART. All statistical analyses were computed using SAS software, Version 9.1.3 of the SAS System for Windows (SAS Institute, Cary, NC).
Results
Clinical and demographic characteristics
The proportion of patients under the age of 50 years was 75% in the combined cohort, and 60% and 84% in AHOD and TAHOD, respectively (Table 1) . Of the younger population, approximately 90% (n = 4725) were aged between 30 and 49 years and the remaining 10% (n = 608) were under the age of 30 years. In the older population, 67% were aged 50-59 years (n = 1210) and 33% (n = 599) were aged 60 years and over. The older population predominately consisted of AHOD patients (62%). Men represented the majority in both the younger and older populations (77% and 89%, respectively). The predominant likely mode of HIV exposure was homosexual contact in AHOD participants and heterosexual contact in TAHOD participants. The proportions of hepatitis B or hepatitis C virus coinfection were similar in the older and younger groups in both AHOD and TAHOD. Older patients had a longer time since HIV diagnosis than younger patients and, similarly, the average duration of cART was greater in the older group (Table 1) . The proportion of patients on their fourth (or more) cART regimen was higher in older patients compared with younger patients (36% vs. 15%, respectively). The anchor agents used in the patient's most recent cART regimen for older and younger patients were proportionally similar. Immunological differences determined from the patients' most recent clinical visit were similar in older and younger patients, and the proportion of patients with detectable HIV RNA viral load was lower in the older population (10% vs. 20% in the younger group).
All-cause mortality
The risk of all-cause mortality increased with age in both univariate and multivariate Cox models (Table 2 ). Relative to persons aged 30-39 years, patients aged 50-59 years had a 2-fold increase (95% CI 1.4-3.8) in risk of all-cause mortality and patients aged ≥ 60 years had a 4-fold increase (95% CI 2.4-7.5) in risk of all-cause mortality. Within each age stratum, there were different proportions of IDU mode of HIV exposure, potentially confounding our results. To adjust for this, we fitted an interaction between younger age and IDU mode of HIV exposure and we found the interaction term to be insignificant (P = 0.38; HR not shown). We found no differences for the association of older age and risk of all-cause mortality between the two cohorts ( Fig. 1) . Cox model assumptions, including the validity of proportional hazards, were not violated.
Immunological responses
CD4 cell count responses to ART varied over time and were largely determined by CD4 cell count at cART initiation ( Table 2 ). The effect of older age on CD4 cell response was statistically insignificant (P-trend = 0.06). However, patients aged ≥ 60 years had statistically poorer immunological responses. Patients in this age group had a mean The interaction term between older age and cohort was statistically insignificant (P = 0.72) and sensitivity analyses showed that the estimated age effects were robust under different model specifications adjusting for time and precART CD4 cell count (data not shown).
Detectable viral load
The odds of detectable viral load were associated with age (Table 2) . Older age groups relative to the reference group (30-39 years) had significantly lower odds of detectable viral load. In the multivariable model, 40-49-year-old patients had a relative odds ratio (OR) of 0.69 (95% CI 0.54-0.89), and patients aged 50-59 and ≥ 60 years had, respectively, ORs of 0.53 (95% CI 0.36-0.78) and 0.55 (95% CI 0.31-0.97). Patients < 30 years old had an increased OR of detectable viral load relative to patients aged 30-39 years. We found no differences in the measured age association between the two cohorts, AHOD and TAHOD (Fig. 2) . Sensitivity analyses were performed to assess the impact of patients who were lost to follow-up and missing records. The resulting age associations were qualitatively similar.
Time to cART regimen change
We found no significant age effect for time to major treatment modification (across all competing risks of switching) (P = 0.21; Table 2 ). The interaction term between age and cohort was insignificant. A strong cohort effect was identified. TAHOD patients were half as likely, relative to AHOD patients, to change treatment (HR 0.59; 95% CI 0.5-0.64) during our study observation period.
Discussion
In this study we found that ageing in HIV-positive APHOD patients was statistically significantly associated with increased all-cause mortality and a decreased likelihood of detectable viral load after cART initiation. Ageing was not significantly associated with a reduced response in CD4 count after treatment initiation, except in patients ≥ 60 years old. We found that age was not associated with time to first major modification of cART, and, importantly, we showed that the patterns of the association between age and all-cause mortality were consistent in HIV-infected patients from resource-rich and resource-limited countries. Many studies have shown an association between older age and increased risk of all-cause mortality [5, 16, 17, 30, 31] . Our results are consistent with this trend with age in terms of magnitude and direction of risk. Additionally, our results are consistent with previous reports that have shown that older HIV-infected populations initiating cART have higher odds of maintaining an undetectable HIV RNA viral load during follow-up [16] [17] [18] [19] [20] [21] . In a prospective cohort study conducted by Nogueras et al., it was hypothesized that this observation is related to better demonstrated treatment adherence in older patients, whom may have more stable lifestyles than younger patients [16] . Others have shown that increases in CD4 cell count following initiation of cART may be blunted in older patients [15] [16] [17] [18] . Our data support this finding, although primarily in older patients (≥ 60 years old). However, the clinical significance of this finding and how it translates into an risk of all-cause mortality remain unclear. The rates of time to first major modification of cART were similar in older and younger HIVpositive patients, which is consistent with other studies that evaluated predictors of early cART modification [20, 29, 32] . Older age is generally not associated with treatment modification.
In this study, our key finding was the lack of statistically significantly different patterns in the association between older age and HIV-related treatment outcomes in resourcerich (AHOD) and resource-limited (TAHOD) countries. The patient demographics, clinical characteristics, availability of cART, clinical care setting and availability of medical resources in AHOD and TAHOD are vastly different [33, 34] . Nevertheless, we report markedly similar ageing associations for all typical HIV-related treatment outcomes and suggest that some results or findings from future ageing studies might be applicable to both resource-rich and resource-limited settings.
There are limitations to our analyses. We do not report any associations between older age and the risk of serious non-AIDS events (SNEs) or other known biomarkers associated with ageing-related morbidity [CD4 : CD8 ratio, d-dimer, interleukin (IL)-6, etc]. We do not collect these data routinely in AHOD and TAHOD; however, collection of SNE data has recently commenced in TAHOD. The two cohorts are substantially different and we have attempted to adjust for this by fitting an interaction term in all of our models. However, within TAHOD there are many different ethnicities, from low-, middle-and high-income countries, which might confound our results. Previous APHOD studies that specifically aimed to compare outcomes between highand low-income countries or between ethnicities found little difference [26, 29, 31, [35] [36] [37] .
In conclusion, this study on HIV and ageing in the Asia Pacific region has shown that older patients on cART maintained better virological control than younger patients. Older patients had marginally poorer CD4 cell responses and a 2-fold higher risk of all-cause mortality. We found no differences in the time to first major modification of cART. Importantly, we did not find any significant difference in the ageing associations of typical HIV-related outcomes between a resource-rich and a predominately resource-limited cohort. As the number of ageing HIV-positive patients increases in the coming years, many will experience typical ageing-related morbidity, perhaps earlier and further complicated by their HIV infection. The general burden of disease in the ageing HIVinfected population and the affect on financial resources are yet to be determined and warrant further investigation.
